Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
Alkermes plc - Ordinary Shares (ALKS)
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-irhome
Company Research
Source: Business Wire
— Augments Alkermes’ Revenue Growth Profile and Diversifies Commercial Portfolio with New High Potential Growth Product, LUMRYZ® (Sodium Oxybate) for Extended-Release Oral Suspension —— Expected to be Accretive in 2026 —— Positions the Combined Organization to Accelerate Innovation and Leadership in Development of Treatments for Sleep Disorders and Other Neurological Disorders — DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) (“Alkermes”) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel”) today announced Alkermes’ completion of its acquisition of Avadel, a commercial-stage biopharmaceutical company. The acquisition adds Avadel’s FDA-approved product, LUMRYZ®, to Alkermes’ commercial portfolio, and provides Alkermes with a commercial organization experienced in this disease state. This strategic move accelerates Alkermes’ entry into the sleep medicine market and enhances its ability to unlock the full potential of its late-stage development pipeline focused on central dis
Show less
Read more
Impact Snapshot
Event Time:
ALKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALKS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALKS alerts
High impacting Alkermes plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ALKS
News
- Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026Business Wire
- Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Alkermes (NASDAQ:ALKS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board [Yahoo! Finance]Yahoo! Finance
- Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1Business Wire
ALKS
Earnings
- 10/28/25 - Beat
ALKS
Sec Filings
- 2/12/26 - Form 8-K
- 2/6/26 - Form 4
- 2/6/26 - Form 4
- ALKS's page on the SEC website